Fig. 7
From: Nanotechnology-based ocular drug delivery systems: recent advances and future prospects
 The schematic illustration of hybrid cell-membrane-cloaked biomimetic nanoparticles taking advantage of the targeting property of REC and the immune evasion capability of RBC for the therapy of laser-induced CNV. A The process of preparing hybrid cell-membrane-coated NPs. B Intravenous administration of NPs absorbs proangiogenic factors, leading to the blocking of their influences on the endothelial cells of the host neovascularization